EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...
EAST HANOVER, N.J., Aug. 17 -- Reclast(R) (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal ...
Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...
EAST HANOVER, N.J., June 5 /PRNewswire/ -- The US Food and Drug Administration (FDA) has broadened the US indication for once-yearly Reclast(R) (zoledronic acid) Injection to include the prevention of ...
The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...
Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...
Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...
The drug Reclast has just been approved by the Food & Drug Administration for a new purpose: the treatment and prevention of osteoporosis. Specifically, patients expected to be on glucocorticoids, or ...
BOSTON (MarketWatch) -- Novartis AG said early Monday that its bone medication Reclast has also been approved by the Food and Drug Administration to treat postmenopausal osteoporosis. The drug, ...
Novartis has been granted US regulatory approval for Reclast, a highly effective treatment for patients with Paget’s disease of the bone, a serious but commonly-overlooked condition that affects ...
EAST HANOVER, N.J., April 11 New data show that aonce-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg wassignificantly better than risedronate at increasing bone mass in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback